This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Alpha interferon in hepatitis D virus hepatitis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

A trial reporting the use of high dose alpha interferon in hepatitis D virus hepatitis suggests that:

  • high dose alpha interferon (9 million units three times weekly) has been shown to result in a complete response in 50% of patients treated. A complete response is defined as a return of aminotransferase levels to normal and clearance of hepatitis delta virus RNA from the serum.
  • 21% of patients were apparently disease free 6 months after therapy.
  • a complete response was less likely to occur with lower doses of alpha interferon.
  • relapse was often delayed - there is evidence that indefinite therapy may be required for a durable response.
  • if hepatitis B is eliminated (HBsAg is cleared from the serum) then it appears that hepatitis D may be cured.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.